Form 4: Scholar Rock R&D President Granted Equity

Scholar Rock Holding Corp's President of R&D, Akshay Vaishnaw, was granted 47,021 restricted stock units, vesting over four years.

Summary

• Akshay Vaishnaw, President of R&D and a Director at Scholar Rock Holding Corp (SRRK), was granted 47,021 Restricted Stock Units (RSUs).
• The transaction date for this acquisition is reported as February 9, 2026.
• These RSUs are subject to time-based vesting conditions, with each RSU representing the contingent right to receive one share of the Issuer's common stock upon vesting.
• The shares subject to this RSU grant will vest in four annual installments over four years, with the first installment vesting on January 15, 2027, and subsequent installments annually thereafter, contingent on continued service.
• Following this reported transaction, Mr. Vaishnaw beneficially owns a total of 642,788 securities.
• This total beneficial ownership includes 45,767 shares of common stock, 147,021 time-based RSUs (including the new grant), and 450,000 performanceand time-based RSUs.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the equity grant aligns executive incentives with long-term shareholder value, a standard and healthy practice for corporate governance and talent retention.

Positives

• The grant of 47,021 Restricted Stock Units (RSUs) to a key executive like the President of R&D aligns management's long-term interests with those of shareholders.
• Equity compensation is a standard practice for attracting and retaining top talent in the biotechnology sector, signaling commitment to executive retention.

Negatives

• The RSUs have no immediate cash value and are subject to a multi-year vesting schedule, meaning the executive must remain with the company to realize the full benefit.
• The value of the RSUs is tied to the future stock performance of Scholar Rock Holding Corp, introducing market risk.

Risks

• The vesting of the RSUs is contingent upon the reporting person's continued service relationship with the Issuer on each vesting date, posing a risk of forfeiture if employment ceases.
• The ultimate value of the RSUs is dependent on the future market price of Scholar Rock's common stock, which is subject to market volatility and company performance.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the scheduled vesting dates for the granted RSUs.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units (RSUs) with multi-year vesting schedules, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. This practice is designed to incentivize long-term performance, align executive interests with shareholder value creation, and aid in executive retention within a highly competitive talent market.

Comparison to Industry Standards

• Equity grants to key executives like the President of R&D are a common compensation strategy across the biotech sector, comparable to practices at companies such as Biogen, Vertex Pharmaceuticals, and Moderna, which frequently use RSUs to reward and retain senior leadership.
• The multi-year, time-based vesting schedule is typical for executive equity awards, ensuring a sustained commitment from the executive, similar to vesting structures seen in major pharmaceutical companies' compensation plans.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive can align management's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: This type of compensation reinforces the company's commitment to retaining key talent, which can positively impact employee morale and stability.

Next Steps

• The first annual installment of the newly granted RSUs is scheduled to vest on January 15, 2027, contingent on the reporting person's continued service.
• Subsequent annual installments will vest annually thereafter over the following three years.

Key Dates

Keywords

Scholar Rock Holding Corp, SRRK, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, Akshay Vaishnaw, Biotechnology, Time-based vesting, Rule 10b5-1